课题基金 / 基金详情

ANTI-IDIOTYPE ANTIBODY APPROACH FOR AN HIV VACCINE

ANTI-IDIOTYPE ANTIBODY APPROACH FOR AN HIV VACCINE
HIV 疫苗的抗独特型抗体方法
批准号:
3489461
负责人:
CHANG-YUIL KANG
金额:
$5.0万
依托单位国家:
美国
项目类别:
财政年份:
1991
资助国家:
美国
项目状态:
已结题
起止时间:
1991-08-15 至 1992-02-14

项目摘要

项目成果

CHANG-YUIL KANG的其他基金

相似基金

相关文献

中文摘要
翻译
描述:(改编自申请人的摘要)试图做一个
英文摘要
DESCRIPTION: (Adapted from the applicant's abstract) Attempts to make a practical HIV vaccine have been unsuccessful to date. The applicant proposes using anti-idiotype antibody (anti-id) as an HIV vaccine to elicit high titers of group-specific neutralizing antibodies. The principle of this approach is based on idiotype matching, which utilizes anti-ids as surrogates for antigen in an attempt to stimulate specific elements of the B cell repertoire in humans. The applicant will generate and characterize a panel of murine anti-id Mabs against human polyclonal anti-gp120 antibodies. The characterization of anti-id Mabs will be achieved by affinity isolation with individual anti-id Mabs which interact with group specific neutralizing anti-gp120 antibodies for further studies in primates. To identify anti-id Mabs of potential utility in eliciting group-specific neutralizing antibodies, monkeys will be immunized with anti-id Mabs and the sera will be evaluated for neutralizing anti-gp120 antibodies. Evaluation of neutralizing antibodies will be done by measurement of anti-gp120 titer in ELISA and virus neutralization assay using various HIV isolates. In Phase II, protection experiments against viral infection in primates and further evaluation of anti-id Mabs as an HIV vaccine in humans, will be performed.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间: 1993
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Kang,CY, Hariharan,K, Posner,MR, Nara,P]
通讯作者: Nara,P
Anti-idiotype monoclonal antibody elicits broadly neutralizing anti-gp120 antibodies in monkeys.
抗独特型单克隆抗体在猴子体内引发广泛中和抗 gp120 抗体。
DOI: 10.1073/pnas.89.7.2546
发表时间: 1992
期刊: Proceedings of the National Academy of Sciences of the United States of America
影响因子: 11.1
作者: [Kang,CY, Nara,P, Chamat,S, Caralli,V, Chen,A, Nguyen,ML, Yoshiyama,H, Morrow,WJ, Ho,DD, Köhler,H]
通讯作者: Köhler,H
Analysis of B cell repertoire specific to the neutralizing epitopes of glycoprotein 120 in HIV-infected individuals.
对 HIV 感染者中糖蛋白 120 中和表位特异的 B 细胞库进行分析。
DOI: 10.1089/aid.1994.10.1629
发表时间: 1994
期刊: AIDS research and human retroviruses
影响因子: 1.5
作者: [Hariharan,K, Nara,PL, Shabazz,LA, McCutchan,JA, Kang,CY]
通讯作者: Kang,CY
DOI: --
发表时间: 1992
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Chamat,S, Nara,P, Berquist,L, Whalley,A, Morrow,WJ, Köhler,H, Kang,CY]
通讯作者: Kang,CY
ANTI-IDIOTYPE ANTIBODY APPROACH FOR AN HIV VACCINE
  • 批准号:
    3506178
  • 项目类别:
  • 资助金额:
    $25.0万
  • 财政年份:
    1991
  • 负责人:
    CHANG-YUIL KANG
  • 依托单位:
ANTI-CD4 ANTIBODY AS THERAPEUTIC/PREVENTIVE HIV VACCINE
  • 批准号:
    3489229
  • 项目类别:
  • 资助金额:
    $5.0万
  • 财政年份:
    1990
  • 负责人:
    CHANG-YUIL KANG
  • 依托单位:
海外基金